Submitted by web@researchtop... on Tue, 07/27/2010 - 17:52
First-in-Human Study of the Oral ALK Inhibitor Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
| CME test | Downloadable PDF | PowerPoint slides | CME Information and Faculty Disclosures |
| Read Dr Love's original email (from July 30, 2010) | Subscribe to Dr Love's email alerts | ||
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Roy S Herbst, MD, PhD (6/23/10), Corey J Langer, MD (7/2/10) and Lecia V Sequist, MD, MPH (6/18/10)
Bang Y et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Proc ASCO 2010;Abstract 3.